Breaking News

Catalent Issues Letter Regarding Pending Acquisition by Novo Holdings

Alessandro Maselli will continue to lead Catalent as President and CEO following the transaction close.

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent has issued an open letter to customers regarding the pending acquisition by Novo Holdings.
 
In the letter, President and Chief Executive Officer of Catalent, Alessandro Maselli, states, “I want to correct a few key inaccuracies that have been reported in the press regarding Novo Holdings’ pending acquisition of Catalent and reiterate that we are, and will continue to be, driven by our mission to develop, manufacture and supply products.”
 
Following the closing of the transaction, according to Maselli, as a private company under Novo Holdings’ ownership, Catalent will continue to operate as a global, independent, full-service CDMO. Catalent’s remaining network of nearly 50 global sites will continue to provide the following: latest technology and capabilities, scalable capacity, regulatory expertise; product development services and clinical trials, and supply client needs for commercial product launch and beyond; offer fill and finish services for sterile products for large and small molecules, including gene and cell therapies.
 
According to the letter Maselli will continue to lead Catalent as President and CEO following the transaction close. 
 
“Since the announcement of this pending acquisition, all of us at Catalent have remained focused on ensuring that a reliable and high-quality supply of products is available for the patients that need them. As a result, Catalent has continued to experience strong levels of new business wins across our offerings, and we are honored by the confidence you place in us and greatly appreciate your loyalty,” said Maselli.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters